CN110156889A

CN110156889A - High-affinity HBs T cell receptor

Info

Publication number: CN110156889A
Application number: CN201810151928.8A
Authority: CN
Inventors: 李懿; 柳其
Original assignee: Guangzhou Institute of Biomedicine and Health of CAS
Current assignee: Guangzhou Institute of Biomedicine and Health of CAS
Priority date: 2018-02-14
Filing date: 2018-02-14
Publication date: 2019-08-23
Anticipated expiration: 2038-02-14
Also published as: WO2019158084A1; CN110156889B

Abstract

The present invention provides a kind of T cell receptor (TCR), have the characteristic in conjunction with ILSPFLPLL-HLA A2 compound；And the TCR is wild type TCR at least 1.3 times of the binding affinity of ILSPFLPLL-HLA A2 compound to the binding affinity of the ILSPFLPLL-HLA A2 compound.Such TCR can be used alone, and can also be combined with therapeutic agent, present ILSPFLPLL-HLA A2 compound tumour cell with targeting.

Description

High-affinity HBs T cell receptor

Technical field

The present invention relates to field of biotechnology, relate more specifically to identify derived from HBV surface antigen (surface Antigen) the T cell receptor (T cell receptor, TCR) of (HBsAg) polypeptide.The invention further relates to the receptors Preparation and use.

Background technique

Only there are two types of the molecules of type to identify antigen in a manner of specificity.One of which be immunoglobulin or Antibody；Another kind is T cell receptor (TCR), it be as α chain/β chain or γ chain/δ chain in the form of heterodimer existing for cell The glycoprotein of film surface.The composition of the TCR score of immune system is to be recombinated in thymus gland by V (D) J, then carry out it is positive and Solid phase and generate.In peripheral ring border, TCR has mediated T cell to main histocompatibility complex-peptide complexes (pMHC) specific recognition, therefore it is vital to the cellular immune function of immune system.

TCR is the unique receptor for presenting the specific antigen peptide on main histocompatibility complex (MHC), this external source Peptide or endogenous peptide may be that cell abnormal unique sign occurs.In immune system, by the TCR of antigentic specificity with The combination of pMHC compound causes T cell and antigen presenting cell (APC) is directly physically contacted, then both T cell and APC Other cell membrane surface molecules just interact, this just causes a series of subsequent cell signals transmitting and other lifes Reason reaction, so that the T cell of different antigentic specificities plays immunological effect to its target cell.

MHC I class corresponding with TCR and II class molecule ligand be also the protein of immunoglobulin superfamily but for The presentation of antigen has specificity, and different individuals has different MHC, so as to present small peptide different in a kind of proteantigen To respective APC cell surface.The MHC of the mankind is commonly referred to as HLA gene or HLA complex.

Small peptide ILSPFLPLL (SEQ ID NO:53) is originated from the liver cancer cells caused by the liver cell of HBV infection or HBV The hepatitis B surface antigen (Roh, S., et al. (2001) .Virus Research 73 (1): 17-26.) of expression.Tumour cell I type HLA molecular presentation it is short from HBV surface antigen (HBV surface antigen) including ILSPFLPLL Peptide.Therefore, ILSPFLPLL-HLA A2 compound provide a kind of TCR can targets neoplastic cells label.It can combine The TCR of ILSPFLPLL-HLA A2 compound has very high application value to the treatment of tumour.For example, the tumour can be targeted The TCR of cell marking can be used for cytotoxic agent or immunostimulant being delivered to target cell, or be transformed into T cell, make table T cell up to the TCR can destroy tumour cell, to give patient in the therapeutic process of referred to as adoptive immunotherapy. For previous purpose, ideal TCR is affinity with higher, is targeted so that the TCR be enable to reside in for a long time Above cell.For latter purpose, then it is preferable to use the TCR of medium affinity.Therefore, those skilled in the art are dedicated to developing It can be used for meeting the TCR of the targets neoplastic cells label of different purposes.

Summary of the invention

The purpose of the present invention is to provide the TCR that a kind of pair of ILSPFLPLL-HLA A2 compound has higher affinity.

Another object of the present invention is to provide the preparation method of the above-mentioned type TCR a kind of and the purposes of the above-mentioned type TCR.

The first aspect of the present invention provides a kind of T cell receptor (TCR), has and combines ILSPFLPLL-HLA A2 The activity of compound.

In another preferred example, the T cell receptor (TCR) has the work in conjunction with ILSPFLPLL-HLA A2 compound Property, and the T cell receptor includes TCR α chain variable domain and TCR β chain variable domain, and the TCR α chain variable domain includes 3 CDR The consensus sequence in area, 3 CDR regions of the TCR α chain variable domain is as follows,

CDR1 α: DRGSQS

CDR2 α: IYSNGD

CDR3 α: AVNLYAGNMLT, and contain at least one following mutation:

Residue before mutation	Residue after mutation
		The 3rd N of CDR3 α	Q or A
The 4th L of CDR3 α	D, E, G, S or H
		The 5th Y of CDR3 α	P, Q, S or G
The 6th A of CDR3 α	S, T, W or D
		The 7th G of CDR3 α	R, K, M, Q, N, T, S or H

And/or the TCR β chain variable domain includes 3 CDR regions, the benchmark sequence of 3 CDR regions of the TCR β chain variable domain Column are as follows,

CDR1 β: SGHVS

CDR2 β: FQNEAQ

CDR3 β: ASSSDFGNQPQH.

In another preferred example, the mutation number of the TCR α chain CDR region can be 1,2,3,4,5.

In another preferred example, T cell receptor (TCR) according to the present invention, can comprising TCR α chain variable domain and TCR β chain Variable domain, the TCR α chain variable domain includes CDR1 α, CDR2 α and CDR3 α.

In another preferred example, the CDR1 α includes sequence: DRGSQS.

In another preferred example, the CDR2 α includes sequence: IYSNGD.

In another preferred example, the CDR3 α includes sequence:

AV [3 α X1] [3 α X2] [3 α X3] [3 α X4] [3 α X5] NMLT, wherein [3 α X1], [3 α X2], [3 α X3], [3 α X4], [3 α X5] independently selected from arbitrary native amino acid residues.

In another preferred example, described [3 α X1] is N, Q or A.

In another preferred example, described [3 α X2] is L, D, E, G, S or H.

In another preferred example, described [3 α X3] is Y, P, Q, S or G.

In another preferred example, described [3 α X4] is A, S, T, W or D.

In another preferred example, described [3 α X5] is G, R, K, M, Q, N, T, S or H.

In another preferred example, the CDR3 α includes sequence selected from the group below:

AVNLYAGNMLT、AVQDPSRNMLT、AVADQSRNMLT、AVQDPSKNMLT、AVQDPSMNMLT、 AVQDPSQNMLT、AVQDPTNNMLT、AVQDSSRNMLT、AVQDPAKNMLT、AVQEPSRNMLT、AVQDPTKNMLT、 AVAGGWRNMLT、AVQSPDRNMLT、AVQHPATNMLT、AVADPSKNMLT、AVAHPSKNMLT、AVQSPDQNMLT、 AVQDPASNMLT、AVQDPSHNMLT、AVQDPSTNMLT。

In another preferred example, T cell receptor (TCR) according to the present invention, can comprising TCR α chain variable domain and TCR β chain Variable domain, the TCR β chain variable domain include CDR1 β, CDR2 β and CDR3 β.

In another preferred example, the CDR1 β includes sequence: SGHVS.

In another preferred example, the CDR2 β includes sequence: FQNEAQ.

In another preferred example, the CDR3 β includes sequence: ASSSDFGNQPQH.

In another preferred example, the TCR α chain variable domain of the TCR does not include following CDR simultaneously:

CDR1 α: DRGSQS；CDR2 α: IYSNGD；With CDR3 α: AVNLYAGNMLT.

In another preferred example, the TCR β chain variable domain of the TCR does not include following CDR simultaneously:

CDR1 β: SGHVS；CDR2 β: FQNEAQ；With CDR3 β: ASSSDFGNQPQH.

In another preferred example, the mutation occurs in α chain and/or one or more CDR regions of β chain variable domain.

In another preferred example, the mutation occurs in the CDR3 of α chain.

In another preferred example, the α chain variable domain amino acid sequence of the TCR is selected from: SEQ ID NO:28-46.

In another preferred example, the affinity of the TCR and ILSPFLPLL-HLA A2 compound be wild type TCR extremely It is 1.3 times few；Preferably, at least 2 times；It is highly preferred that at least 5 times.

In another preferred example, the affinity of the TCR and ILSPFLPLL-HLA A2 compound be wild type TCR extremely It is 10 times few；Preferably, at least 20 times.

In another preferred example, Dissociation equilibrium constant K of the TCR to ILSPFLPLL-HLA A2 compound_D≤3.4μ M。

In another preferred example, Dissociation equilibrium constant 10nM≤K of the TCR to ILSPFLPLL-HLA A2 compound_D ≤2.58μM；Preferably, 100nM≤K_D≤700nM。

In another preferred example, the TCR has CDR selected from the group below:

TCR number

CDR1α

CDR2α

CDR3α

CDR1β

CDR2β

CDR3β

s-1

DRGSQS

IYSNGD

AVQDPSRNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-2

DRGSQS

IYSNGD

AVADQSRNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-3

DRGSQS

IYSNGD

AVQDPSKNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-4

DRGSQS

IYSNGD

AVQDPSMNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-5

DRGSQS

IYSNGD

AVQDPSQNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-6

DRGSQS

IYSNGD

AVQDPTNNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-7

DRGSQS

IYSNGD

AVQDSSRNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-8

DRGSQS

IYSNGD

AVQDPAKNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-9

DRGSQS

IYSNGD

AVQEPSRNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-10

DRGSQS

IYSNGD

AVQDPTKNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-11

DRGSQS

IYSNGD

AVAGGWRNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-12

DRGSQS

IYSNGD

AVQSPDRNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-13

DRGSQS

IYSNGD

AVQHPATNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-14

DRGSQS

IYSNGD

AVADPSKNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-15

DRGSQS

IYSNGD

AVAHPSKNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-16

DRGSQS

IYSNGD

AVQSPDQNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-17

DRGSQS

IYSNGD

AVQDPASNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-18

DRGSQS

IYSNGD

AVQDPSHNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

s-19

DRGSQS

IYSNGD

AVQDPSTNMLT

SGHVS

FQNEAQ

ASSSDFGNQPQH

In another preferred example, the TCR is soluble.

In another preferred example, the TCR is α β heterogeneous dimerization TCR or single-stranded TCR.

In another preferred example, TCR of the present invention is the heterogeneous dimerization TCR of α β, the α chain variable domain of the TCR include with Amino acid sequence shown in SEQ ID NO:24 has at least 85%, it is preferable that at least 90%；It is highly preferred that at least 92%；Most Preferably, at least 94% (e.g., can be at least 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence homology) sequence homology amino acid sequence；And/or the β chain variable domain packet of the TCR Containing having at least 90% with amino acid sequence shown in SEQ ID NO:25, it is preferable that at least 92%；It is highly preferred that at least 94%； Most preferably, at least 97%；(it e.g., can be at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% Sequence homology) sequence homology amino acid sequence.

In another preferred example, the TCR includes all or part of TCR α chain of (I) in addition to its transmembrane domain, and The all or part of TCR β chain of (II) in addition to its transmembrane domain, wherein (I) and (II) is comprising variable domain and extremely of TCR chain Few a part of constant domain.

In another preferred example, the TCR is the heterogeneous dimerization TCR of α β, the α chain variable region of the TCR and β chain constant region it Between contain artificial interchain disulfide bond.

In another preferred example, artificial interchain disulfide bond is formed between the α chain variable region of the TCR and β chain constant region Cysteine residues instead of be selected from following one or more groups of sites:

The 46th amino acids of TRAV and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1；

The 47th amino acids of TRAV and 61 amino acids of TRBC1*01 or TRBC2*01 exons 1；

The 46th amino acids of TRAV and the 61st amino acids of TRBC1*01 or TRBC2*01 exons 1；Or

The 47th amino acids of TRAV and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1.

Wherein, amino acid sequence positions number is compiled by the position listed in IMGT (international immunogenetics information system) Number.

In another preferred example, the TCR between α chain variable region and β chain constant region containing artificial interchain disulfide bond includes α chain Variable domain and β chain variable domain and all or part of β chain constant domain in addition to transmembrane domain, but it does not contain α chain is constant Domain, the α chain variable domain and β chain of the TCR form heterodimer.

In another preferred example, the TCR between α chain variable region and β chain constant region containing artificial interchain disulfide bond includes (I) All or part of TCR α chain in addition to its transmembrane domain, and all or part of TCR β of (II) in addition to its transmembrane domain Chain, wherein (I) and (II) includes the variable domain and at least part constant domain of TCR chain.

In another preferred example, the TCR is the heterogeneous dimerization TCR of α β, and it is complete in addition to its transmembrane domain that it includes (I) Portion or part TCR α chain, and all or part of TCR β chain of (II) in addition to its transmembrane domain, wherein (I) and (II) includes The variable domain and at least part constant domain of TCR chain contain artificial interchain disulfide bond between α chain constant region and β chain constant region.

In another preferred example, half Guang ammonia of artificial interchain disulfide bond is formed between the TCR α and the constant region of β chain Sour residue is instead of selected from following one or more groups of sites:

The Ser57 of Thr48 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；

The Ser77 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；

The Ser17 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；

The Asp59 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；

The Glu15 of Ser15 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；

The Ser54 of Arg53 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；TRAC*01 exon The Ala19 of 1 Pro89 and TRBC1*01 or TRBC2*01 exons 1；With

The Glu20 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1.

In another preferred example, the TCR is single-stranded TCR.

In another preferred example, the single-stranded TCR that the TCR is made of α chain variable domain and β chain variable domain, the α chain can Variable domain and β chain variable domain are connected by a flexible short peptide sequence (linker).

In another preferred example, the hydrophobic core of the TCR mutates.

In another preferred example, the hydrophobic core of the TCR α chain variable domain and/or β chain variable domain mutates.

In another preferred example, the TCR that the hydrophobic core mutates is made of single-stranded α variable domain and β variable domain TCR, the α variable domain and β variable domain are connected by a flexible short peptide sequence (linker).

In another preferred example, TCR of the present invention is single-stranded TCR, and the α chain variable domain of the TCR includes and SEQ ID Amino acid sequence shown in NO:2 has at least 85%, it is preferable that at least 90%；It is highly preferred that at least 92%；Most preferably, until It is few 94% (e.g., can be at least 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence homology) sequence homology amino acid sequence；And/or the β chain variable domain of the TCR includes and SEQ ID Amino acid sequence shown in NO:3 has at least 90%, it is preferable that at least 92%；It is highly preferred that at least 94%；Most preferably, until Few 97%；(it e.g., can be at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence homology Property) sequence homology amino acid sequence.

In another preferred example, the α chain variable domain amino acid sequence of the TCR is selected from: SEQ ID NO:5-23.

In another preferred example, the choosing of the α chain variable domain shown in SEQ ID NO:24 occurs for the hydrophobic core mutation of the TCR From one or more acid residues sites of the following group: 19A, 21L, 39Y, 40S, 79S and 88L；Wherein, numbering amino acid residues It is numbered using shown in SEQ ID NO:24；And/or

One or more ammonia selected from the group below of the β chain variable domain shown in SEQ ID NO:25 occur for the hydrophobic core mutation Base acid Residue positions: 11K, 13A, 36Q, 38A, 39L, 43P, 82T, 84Q, 91L and 113I, wherein numbering amino acid residues are adopted It is numbered shown in SEQ ID NO:25.

In another preferred example, the α chain variable domain of the TCR after the mutation of hydrophobic core includes one selected from the group below or more A amino acid residue: 19V, 21I, 39D, 40P, 79V and 88F；And/or the β chain variable domain packet of the TCR after hydrophobic core mutation Include one or more amino acid residues selected from the group below: 11L, 13V, 36R, 38D, 39P, 43L, 82V, 84P, 91F and 113V.

In a preferred embodiment of the invention, the T cell receptor (TCR) has and combines The activity of ILSPFLPLL-HLA A2 compound, and include TCR α chain variable domain and TCR β chain variable domain, the TCR is in SEQ ID Mutate in α chain variable domain shown in NO:24, the acid residues sites of the mutation include 92N, 93L, 94Y, 95A or One or more of 96G, wherein numbering amino acid residues are numbered using shown in SEQ ID NO:24.

In another preferred example, the TCR α chain variable domain after mutation includes one or more amino acid selected from the group below Residue: 92Q or 92A；93D, 93E, 93G, 93S or 93H；94P, 94Q, 94S or 94G；95S, 95T, 95W or 95D；96R,96K, 96M, 96Q, 96N, 96T, 96S or 96H；Wherein, numbering amino acid residues are numbered using shown in SEQ ID NO:24.

In another preferred example, the TCR is selected from the group:

In another preferred example, the α chain of the TCR and/or the end C- or N- of β chain are combined with conjugate.

In another preferred example, the conjugate in conjunction with the TCR is detectable marker, therapeutic agent, PK modified part Or the combination of any of these substances.

In another preferred example, the therapeutic agent in conjunction with the TCR is the end C- or N- for being connected to α the or β chain of the TCR The anti-CD 3 antibodies at end.

The second aspect of the present invention provides a kind of multivalent TCR complex, contains at least two TCR molecule, and wherein At least one TCR molecule be first aspect present invention described in TCR.

The third aspect of the present invention, provides a kind of nucleic acid molecules, and the nucleic acid molecules include to encode first party of the present invention The nucleic acid sequence or its complementary series of multivalent TCR complex described in TCR molecule or second aspect of the present invention described in face；

The fourth aspect of the present invention, provides a kind of carrier, and the carrier contains core described in third aspect present invention Acid molecule.

The fifth aspect of the present invention provides a kind of host cell, contains present invention four directions in the host cell Nucleic acid molecules described in the third aspect present invention of external source are integrated in carrier described in face or chromosome.

The sixth aspect of the present invention, provides a kind of isolated cell, and the cell is expressed described in first aspect present invention TCR.

The seventh aspect of the present invention, provides a kind of pharmaceutical composition, and the composition contains pharmaceutically acceptable load TCR compound described in TCR described in body and first aspect present invention or second aspect of the present invention or the 6th side of the invention Cell described in face.

The eighth aspect of the present invention provides a kind of method for treating disease, including suitable to object in need for the treatment of application TCR compound or sixth aspect present invention described in TCR described in the first aspect present invention of amount or second aspect of the present invention Pharmaceutical composition described in the cell or seventh aspect present invention.

The ninth aspect of the present invention provides described in TCR described in first aspect present invention or second aspect of the present invention The purposes of cell described in TCR compound or sixth aspect present invention is used to prepare the drug for the treatment of tumour.

The tenth aspect of the present invention provides a kind of method for preparing T cell receptor described in first aspect present invention, packet Include step:

(i) host cell described in fifth aspect present invention is cultivated, to express T cell described in first aspect present invention Receptor；

(ii) isolated or purified goes out the T cell receptor.

It should be understood that above-mentioned each technical characteristic of the invention and having in below (eg embodiment) within the scope of the present invention It can be combined with each other between each technical characteristic of body description, to form a new or preferred technical solution.As space is limited, exist This no longer tires out one by one states.

Detailed description of the invention

Fig. 1 a and Fig. 1 b are respectively the amino acid sequence and DNA sequence dna for the single-stranded template TCR that the present invention constructs.

Fig. 2 a and Fig. 2 b are respectively that the amino acid sequence of the α variable domain for the single-stranded template TCR that the present invention constructs and β chain can be changed The amino acid sequence in domain.

Fig. 3 a and Fig. 3 b are respectively the DNA sequence dna and β chain variable domain of the α variable domain for the single-stranded template TCR that the present invention constructs DNA sequence dna.

Fig. 4 a and Fig. 4 b are respectively the amino acid sequence of the connection small peptide (linker) for the single-stranded template TCR that the present invention constructs And nucleotide sequence.

The α chain that Fig. 5 a-s respectively illustrates the single-stranded TCR for having high-affinity to ILSPFLPLL-HLA A2 compound can The residue of domain amino acid sequence, mutation is indicated with underlining.

Fig. 6 a and Fig. 6 b respectively illustrate the wild type TCR that can be specifically bound to ILSPFLPLL-HLA A2 compound α and β chain variable domain amino acid sequence.

Fig. 7 a and Fig. 7 b respectively illustrate the amino acid sequence of reference TCR α and β chain in the present invention.

Fig. 8 a-s respectively illustrates the α for the heterogeneous dimerization TCR for having high-affinity to ILSPFLPLL-HLA A2 compound The residue of chain variable domain amino acid sequence, mutation is indicated with underlining.

Fig. 9 is wild type TCR (i.e. reference TCR) and the affinity curve to ILSPFLPLL-HLA A2 compound.

Figure 10 a and Figure 10 b respectively illustrate the amino acid sequence of wild type TCR α and β chain in the present invention.

Figure 11 a-h respectively illustrates the effector cell for transfecting part high-affinity TCR of the invention for load small peptide The Elispot experimental result picture of T2 cell.

The effector cell that Figure 12 a-h respectively illustrates transfection part high-affinity TCR of the invention is thin for unloaded T2 Born of the same parents and loading concentrations 10^-6The Elispot experimental result picture of the T2 cell of the specific small peptide of M.

Specific embodiment

The present invention obtains a kind of identification ILSPFLPLL small peptide and (is derived from HBV by extensive and in-depth research Surface Antigen) high-affinity T cell receptor (TCR), the ILSPFLPLL small peptide is with peptide (peptide)-HLA The form of A2 compound is rendered.3 CDR regions of the high-affinity TCR in its α chain variable domain

CDR1 α: DRGSQS

CDR2 α: IYSNGD

It mutates in CDR3 α: AVNLYAGNMLT；And/or 3 CDR regions in its β chain variable domain

CDR1 β: SGHVS

CDR2 β: FQNEAQ

It mutates in CDR3 β: ASSSDFGNQPQH；Also, TCR of the present invention is to above-mentioned ILSPFLPLL-HLA after being mutated The affinity of A2 compound and/or combination half-life period are at least 1.3 times of wild type TCR.

Before describing the present invention, it should be understood that the present invention is not limited to the specific method and experiment conditions, because this Class method and condition can change.It should also be understood that its purpose of the term as used herein is only that description specific embodiment, and And it is not intended to restrictive, the scope of the present invention will be limited only by the claims which follow.

Unless otherwise defined, otherwise whole technologies used herein and scientific term all have such as fields of the present invention The normally understood identical meanings of those of ordinary skill.

Although can be used in implementation or test of the invention and heretofore described similar or of equal value any method And material, place enumerates preferred method and material herein.

Term

T cell receptor (T cell receptor, TCR)

TCR can be described using international immunogenetics information system (IMGT).Natural α β heterodimeric TCR has α Chain and β chain.In a broad sense, each chain includes variable region, bonding pad and constant region, and β chain is usually also between variable region and bonding pad Containing short variable region, but the variable region is often regarded as a part of bonding pad.It is determined by the TRAJ and TRBJ of unique IMGT The bonding pad of TCR determines the constant region of TCR by the TRAC and TRBC of IMGT.

Each variable region includes 3 CDR (complementary determining region) being entrenched in Frame sequence, CDR1, CDR2 and CDR3.? In IMGT nomenclature, the different numbers of TRAV and TRBV respectively refer to the type for different V α types and V β.In IMGT system, α Chain constant domain has symbol below: TRAC*01, wherein " TR " indicates T cell receptor gene；" A " indicates α chain gene；C Indicate constant region；" * 01 " indicates allele 1.β chain constant domain has symbol below: TRBC1*01 or TRBC2*01, Wherein " TR " indicates T cell receptor gene；" B " indicates β chain gene；C indicates constant region；" * 01 " indicates allele 1.α chain Constant region uniquely determines, and in the form of β chain, there are two possible constant region genes " C1 " and " C2 ".This field skill Art personnel can obtain the constant region gene sequences of TCR α Yu β chain by disclosed IMGT database.

α the and β chain of TCR generally regards that each there are two " structural domain " i.e. variable domain and constant domains as.Variable domain is by connecting Variable region and bonding pad constitute.Therefore, in the description and claims of this application, " TCR α chain variable domain " refers to connection The area TRAV and TRAJ, similarly, " TCR β chain variable domain " refers to the area TRBV and TRBD/TRBJ of connection.The 3 of TCR α chain variable domain A CDR is respectively CDR1 α, CDR2 α and CDR3 α；3 CDR of TCR β chain variable domain are respectively CDR1 β, CDR2 β and CDR3 β.This Invent TCR variable domain Frame sequence can for source of mouse or source of people, preferably source of people.The constant domain of TCR includes Intracellular part, transmembrane region and extracellular portion.To obtain sTCR, to measure TCR and ILSPFLPLL-HLA A2 compound Between affinity, TCR of the present invention do not include transmembrane region preferably.It is highly preferred that the amino acid sequence of TCR of the present invention refers to The extracellular amino acid sequence of TCR.

The α chain amino acid sequence and β chain amino acid sequence of heretofore described " wild type TCR " are respectively SEQ ID NO: 51 and SEQ ID NO:52, as shown in figures 10 a and 10b.The α chain amino acid sequence and β chain ammonia of heretofore described " reference TCR " Base acid sequence is respectively SEQ ID NO:26 and SEQ ID NO:27, as illustrated in figs. 7 a and 7b.In the present invention, it can combine α and β the chain variable domain amino acid sequence of the wild type TCR of ILSPFLPLL-HLA A2 compound be respectively SEQ ID NO:24 and SEQ ID NO:25, as shown in figure 6 a and 6b.In the present invention, term " polypeptide of the present invention ", " TCR of the invention ", " present invention T cell receptor " be used interchangeably.

In another preferred example, the TCR includes TCR α chain variable domain and TCR β chain variable domain, the TCR β chain variable domain Comprising CDR1 β, CDR2 β and CDR3 β, wherein the CDR1 β includes sequence: SGHVS.

In another preferred example, CDR2 β includes sequence: FQNEAQ.

In another preferred example, CDR3 β includes sequence: ASSSDFGNQPQH.

In one, ground of the invention preferably embodiment, T cell receptor (TCR) according to the present invention includes TCR α chain Variable domain and TCR β chain variable domain, the TCR α chain variable domain includes CDR1 α, CDR2 α and CDR3 α.

In another preferred example, the CDR1 α includes sequence: DRGSQS.

In another preferred example, the CDR2 α includes sequence: IYSNGD.

In another preferred example, the CDR3 α includes sequence:

In another preferred example, described [3 α X1] is N, Q or A.

In another preferred example, described [3 α X2] is L, D, E, G, S or H.

In another preferred example, described [3 α X3] is Y, P, Q, S or G.

In another preferred example, described [3 α X4] is A, S, T, W or D.

CDR1 α: DRGSQS；CDR2 α: IYSNGD；With CDR3 α: AVNLYAGNMLT.

Native interchain disulfide bond and artificial interchain disulfide bond

Natural TCR membrane-proximal region C α and C β interchain exist one group of disulfide bond, the present invention in referred to as " two sulphur of native interchain Key ".In the present invention, by what is be artificially introduced, the position interchain covalent disulfide bonds different from the position of native interchain disulfide bond claim For " artificial interchain disulfide bond ".

For convenience of description, the Position Number of TRAC*01 and TRBC1*01 or TRBC2*01 amino acid sequence is pressed in the present invention Sequence successively carries out Position Number from N-terminal to C-terminal, in TRBC1*01 or TRBC2*01, by successively suitable from N-terminal to C-terminal The 60th amino acid of sequence is P (proline), then can describe it as TRBC1*01 or TRBC2*01 exons 1 in the present invention Pro60 can also be stated that the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1, for another example TRBC1*01 or In TRBC2*01, it is Q (glutamine) by the 61st amino acid of the sequence from N-terminal to C-terminal successively, then can be retouched in the present invention It states as the Gln61 of TRBC1*01 or TRBC2*01 exons 1, can also be stated that TRBC1*01 or TRBC2*01 exons 1 The 61st amino acids, other and so on.In the present invention, the Position Number of the amino acid sequence of variable region TRAV and TRBV, According to the Position Number listed in IMGT.Such as some amino acid in TRAV, the Position Number listed in IMGT is 46, then this hair The 46th amino acids of TRAV, other and so on are described it as in bright.In the present invention, the Sequence position numbers of other amino acid There is specified otherwise, then presses specified otherwise.

Tumour

Term " tumour " refers to that, including all types of growth of cancer cells or oncogenic process, metastatic tissue or vicious transformation are thin Born of the same parents, tissue or organ, regardless of histological type or the stage infected.The embodiment of tumour includes: solid tumor without limitation, and soft group Knit tumor and metastasis (metastases).The embodiment of solid tumor includes: the malignant tumour of Different Organs system, such as sarcoma, lung squamous cancer and Cancer.Such as: the prostate of infection, lung, breast, lymph, stomach (such as: colon) and genitourinary tract (such as: kidney, on Chrotoplast), pharynx.Lung squamous cancer includes malignant tumour, for example, most colon cancers, the carcinoma of the rectum, clear-cell carcinoma, liver cancer, lung Non-small cell carcinoma, carcinoma of small intestine and cancer of the esophagus.Above-mentioned cancer metastasis venereal disease become can equally with method and composition of the invention come It treats and prevents.

Detailed description of the invention

It is well known that the α chain variable domain of TCR and β chain variable domain respectively contain 3 CDR, the complementation similar to antibody is determined Area.CDR3 and antigen small peptide interact, and CDR1 and CDR2 and HLA interact.Therefore, the CDR of TCR molecule determine its with The interaction of antigen small peptide-HLA compound.The present inventor is according to can combine antigen small peptide ILSPFLPLL and HLA A2 multiple Close the α chain variable domain amino acid sequence and β chain variable domain ammonia of the wild type TCR of object (that is, ILSPFLPLL-HLA A2 compound) Base acid sequence is respectively SEQ ID NO:24 and SEQ ID NO:25.It is with following CDR region:

α chain variable domain CDR CDR1 α: DRGSQS

CDR2 α: IYSNGD

CDR3 α: AVNLYAGNMLT

With β chain variable domain CDR CDR1 β: SGHVS

CDR2 β: FQNEAQ

CDR3 β: ASSSDFGNQPQH

The present invention obtains the parent with ILSPFLPLL-HLA A2 compound by carrying out screen mutation to above-mentioned CDR region It is the high-affinity TCR of wild type TCR Yu at least 1.3 times of ILSPFLPLL-HLA A2 compound affinity with power.

The present invention provides a kind of T cell receptor (TCR), have the work in conjunction with ILSPFLPLL-HLA A2 compound Property.

The T cell receptor includes TCR α chain variable domain and TCR β chain variable domain, and the TCR α chain variable domain includes 3 The consensus sequence of CDR region, 3 CDR regions of the TCR α chain variable domain is as follows,

CDR1 α: DRGSQS

CDR2 α: IYSNGD

CDR3 α: AVNLYAGNMLT, and contain at least one following mutation:

CDR1 β: SGHVS

CDR2 β: FQNEAQ

CDR3 β: ASSSDFGNQPQH.

In more detail, the mutation number of the TCR α chain CDR region is 1,2,3,4,5.

Further, TCR of the present invention is the heterogeneous dimerization TCR of α β, and the α chain variable domain of the TCR includes and SEQ ID Amino acid sequence shown in NO:24 has at least 85%, it is preferable that at least 90%；It is highly preferred that at least 92%；Most preferably, At least 94% (e.g., can be at least 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence homology) sequence homology amino acid sequence；And/or the β chain variable domain of the TCR includes and SEQ ID Amino acid sequence shown in NO:25 has at least 90%, it is preferable that at least 92%；It is highly preferred that at least 94%；Most preferably, until Few 97%；(it e.g., can be at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence homology Property) sequence homology amino acid sequence.

Further, TCR of the present invention is single-stranded TCR, the α chain variable domain of the TCR include with shown in SEQ ID NO:2 Amino acid sequence have at least 85%, it is preferable that at least 90%；It is highly preferred that at least 92%；Most preferably, at least 94% (it e.g., can be at least 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence Column homology) sequence homology amino acid sequence；And/or the β chain variable domain of the TCR includes and SEQ ID NO:3 institute The amino acid sequence shown has at least 90%, it is preferable that at least 92%；It is highly preferred that at least 94%；Most preferably, at least 97%； The sequence of (e.g., can be at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence homology) The amino acid sequence of homology.

Preferably, the TCR includes all or part of TCR α chain of (I) in addition to its transmembrane domain, and (II) removes it All or part of TCR β chain other than transmembrane domain, wherein (I) and (II) includes the variable domain and at least part of TCR chain Constant domain.

3 CDR, that is, CDR1, the CDR2 of wild type TCR α chain variable domain SEQ ID NO:24 and CDR3 distinguish position in the present invention In 27-32,50-55 and 90-100 of SEQ ID NO:24.Accordingly, numbering amino acid residues use SEQ ID It is numbered shown in NO:24,51Y is the 2nd Y of CDR2 α, and 52S is the 3rd S of CDR2 α, and 53N is the 4th of CDR2 α N, 54G are the 5th G of CDR2 α, and 55D is the 6th D of CDR2 α, and 91V is the 2nd V of CDR3 α, and 96G is CDR3 α The 7th G, 97N is the 8th N of CDR3 α, and 98M is the 9th M of CDR3 α, and 99L is the 10th L, 100T of CDR3 α As the 11st of CDR3 α the T.

Similarly, the present invention in wild type TCR β chain variable domain SEQ ID NO:25 3 CDR, that is, CDR1, CDR2 and CDR3 It is located at 27-31,49-54 and 93-104 of SEQ ID NO:25.Therefore, numbering amino acid residues use It is numbered shown in SEQ ID NO:25,27S is the 1st S of CDR1 β, and 28G is the 2nd G of CDR1 β, and 29H is CDR1 β The 3rd H, 30V is the 4th V of CDR1 β, and 31S is the 5th S of CDR1 β, and 96S is the 4th S of CDR3 β, and 97D is It is the 6th F of CDR3 β for the 5th D of CDR3 β, 98F, 99G is the 7th G of CDR3 β, and 100N is the 8 of CDR3 β Position N, 101Q is the 9th Q of CDR3 β.

The present invention provides the TCR with the characteristic in conjunction with ILSPFLPLL-HLA A2 compound, and includes that TCR α chain is variable Domain and TCR β chain variable domain, the TCR mutate in the α chain variable domain shown in SEQ ID NO:24, the ammonia of the mutation Base acid Residue positions include one or more of 92N, 93L, 94Y, 95A or 96G, wherein numbering amino acid residues use SEQ It is numbered shown in ID NO:24.

It, will be outside wild type TCR α chain constant region TRAC*01 according to the method for rite-directed mutagenesis well known to those skilled in the art The Thr48 of aobvious son 1 sports cysteine, and the Ser57 of β chain constant region TRBC1*01 or TRBC2*01 exons 1 sports half Cystine is to get reference TCR is arrived, and respectively as illustrated in figs. 7 a and 7b, the cysteine residues after mutation are to add for amino acid sequence Thick letter indicates.Above-mentioned cysteine, which replaces, forms artificial interchain disulfide bond between the constant region of the α and β chain that can make reference TCR, To form more stable sTCR, so as to more easily assess TCR and ILSPFLPLL-HLA A2 compound it Between binding affinity and/or combine half-life period.It should be understood that the CDR region of the variable region TCR determines it between pMHC compound Affinity, therefore, the cysteine of above-mentioned TCR constant region replace can't binding affinity to TCR and/or combine partly decline Phase has an impact.So in the present invention, the combination parent between reference TCR and ILSPFLPLL-HLA the A2 compound measured And power is the binding affinity being considered between wild type TCR and ILSPFLPLL-HLA A2 compound.Similarly, if measured Binding affinity between TCR and ILSPFLPLL-HLA A2 compound of the present invention is reference TCR and ILSPFLPLL-HLA A2 At least 1.3 times of binding affinity between compound, that is, be equal to TCR of the present invention and ILSPFLPLL-HLA A2 compound it Between binding affinity be at least 1.3 times of the binding affinity between wild type TCR and ILSPFLPLL-HLA A2 compound.

Binding affinity can be measured by any suitable method (with Dissociation equilibrium constant K_DBe inversely proportional) and combine partly decline Phase (is expressed as T_1/2).It will be appreciated that the affinity of TCR is double to will lead to K_DHalve.T_1/2In2 is calculated as divided by dissociation rate (K_off).Therefore, T_1/2It is double to will lead to K_offHalve.It is preferred that detecting the binding affinity of given TCR using identical testing program Or combine half-life period for several times, such as 3 times or more, take the average value of result.In a preferred embodiment, using implementing herein Surface plasmon resonance (BIAcore) method in example carries out these detections.This method detects TCR pairs of reference The Dissociation equilibrium constant K of ILSPFLPLL-HLA A2 compound_DIt is 3.4 μM, TCR pairs of wild type is thought in the present invention The Dissociation equilibrium constant K of ILSPFLPLL-HLA A2 compound_DIt also is 3.4 μM.It will lead to K since the affinity of TCR is double_DSubtract Half, so if detecting high-affinity TCR to the Dissociation equilibrium constant K of ILSPFLPLL-HLA A2 compound_DIt is 0.34 μM, then Illustrate that high-affinity TCR is wild type TCR to ILSPFLPLL-HLA to the affinity of ILSPFLPLL-HLA A2 compound 10 times of the affinity of A2 compound.The known K of those skilled in the art_DThe conversion relation being worth between unit, i.e. 1 μM=1000nM, 1nM=1000pM.

In a preference of the invention, the affinity of the TCR and ILSPFLPLL-HLA A2 compound is wild At least 1.3 times of type TCR；Preferably, at least 2 times；It is highly preferred that at least 5 times.

In another preferred example, Dissociation equilibrium constant K of the TCR to ILSPFLPLL-HLA A2 compound_D≤3.4μ M；

Any suitable method can be used to be mutated, including but not limited to according to polymerase chain reaction (PCR) that A bit, according to the clone of restriction enzyme or clone (LIC) method of connection is not depended on.Many standard molecular biology teaching materials detail These methods.The more details of polymerase chain reaction (PCR) mutagenesis and the clone according to restriction enzyme can be found in Sambrook And Russell, (2001) Molecular Cloning-A Laboratory handbook (Molecular Cloning-A Laboratory Manual) (the Three editions) CSHL publishing house.Visible (Rashtchian, (1995) Curr Opin Biotechnol 6 of the more information of LIC method (1):30-6)。

The method for generating TCR of the invention can be but not limited to the diversity from the phage particle for showing such TCR The TCR that there is high-affinity to ILSPFLPLL-HLA-A2 compound is filtered out in library, such as document (Li, et al (2005) Nature Biotech 23 (3): 349-354) described in.

It should be understood that the wild type that the gene or expression of expression wild type TCR α and β chain variable domain amino acid are slightly modified The gene of the α and β chain variable domain amino acid of TCR can be adopted to preparation template TCR.Then in the variable domain of coding template TCR DNA in introduce generate high-affinity TCR of the invention needed for change.

In some preferred embodiments of the invention, TCR of the present invention α chain variable domain ammonia shown in SEQ ID NO:24 There are one or more mutations (using shown in SEQ ID NO:24 in base acid residue 92N, 93L, 94Y, 95A or 96G Number).For example, the TCR α chain variable domain after mutation includes one or more amino acid residue selected from the group below: 92Q or 92A；93D, 93E, 93G, 93S or 93H；94P, 94Q, 94S or 94G；95S, 95T, 95W or 95D；96R,96K,96M,96Q, 96N, 96T, 96S or 96H.More specifically, the concrete form of mutation described in α chain variable domain includes N92Q/A, L93D/E/G/S/ H, one group in Y94P/Q/S/G, A95S/T/W/D or G96R/K/M/Q/N/T/S/H or several groups.

High-affinity TCR of the invention include α chain variable domain amino acid sequence SEQ ID NO:28,29,30,31,32, 33, one of 34,35,36,37,38,39,40,41,42,43,44,45,46.Therefore, the β chain variable domain ammonia containing wild type TCR The TCR β chain of base acid sequence (SEQ ID NO:25) can with comprising SEQ ID NO:28,29,30,31,32,33,34,35,36, 37, one of 38,39,40,41,42,43,44,45,46 TCR α chain combines to form heterogeneous dimerization TCR or single chain TCR molecules.This In invention, the amino acid sequence of the α chain variable domain and β chain variable domain that form heterogeneous dimerization TCR molecule preferably is selected from the following table 1:

Based on the purpose of the present invention, TCR of the present invention is the part at least one TCR α and/or TCR β chain variable domain. They usually include TCR α chain variable domain and TCR β chain variable domain simultaneously.They can be α β heterodimer or single stranded form Or other any forms that can be stabilized.It, can be by the overall length chain of α β heterodimeric TCR in adoptive immunotherapy (including cytoplasm and transmembrane domain) is transfected.TCR of the present invention can be used as the target that therapeutic agent is delivered to antigen presenting cell Bifunctional polypeptides are prepared to agent or in conjunction with other molecules and carry out directionality effect cell, and TCR is preferably soluble form at this time.

For stability, discloses introduce artificial interchain two between α the and β chain constant domain of TCR in the prior art Sulfide linkage can obtain solvable and stable TCR molecule, as described in patent document PCT/CN2015/093806.Therefore, of the invention TCR can be the TCR that artificial interchain disulfide bond is introduced between the residue of itself α and β chain constant domain.Cysteine residues are described Artificial interchain disulfide bond is formed between α the and β chain constant domain of TCR.Cysteine residues can be substituted in appropriate site in natural TCR Other amino acid residues to form artificial interchain disulfide bond.For example, replacing Thr48 and the substitution of TRAC*01 exons 1 The Ser57 of TRBC1*01 or TRBC2*01 exons 1 forms disulfide bond.Introduce cysteine residues with formed disulfide bond its His site may also is that the Ser77 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；TRAC* The Ser17 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of 01 exons 1；The Thr45 of TRAC*01 exons 1 and The Asp59 of TRBC1*01 or TRBC2*01 exons 1；Outside the Ser15 and TRBC1*01 or TRBC2*01 of TRAC*01 exons 1 The Glu15 of aobvious son 1；The Ser54 of Arg53 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；TRAC*01 The Ala19 of Pro89 and TRBC1*01 or the TRBC2*01 exons 1 of exons 1；Or the Tyr10 of TRAC*01 exons 1 and The Glu20 of TRBC1*01 or TRBC2*01 exons 1.I.e. cysteine residues are instead of any group in above-mentioned α and β chain constant domain Site.Can one or more C-terminals of TCR constant domain of the present invention truncate it is most 15 or it is most 10 or it is most 8 or Less amino acid can also pass through so that it does not include cysteine residues to achieve the purpose that lack native interchain disulfide bond The cysteine residues for forming native interchain disulfide bond are sported into another amino acid to reach above-mentioned purpose.

As described above, TCR of the invention may be embodied in the artificial interchain two introduced between the residue of itself α and β chain constant domain Sulfide linkage.It should be noted that the artificial disulfide bond with or without introducing described above between constant domain, TCR of the invention can contain TRAC constant domain sequence and TRBC1 or TRBC2 constant domain sequence.The TRAC constant domain sequence and TRBC1 or TRBC2 of TCR is constant Domain sequence can be connected by the native interchain disulfide bond being present in TCR.

In addition, patent document PCT/CN2016/077680 is also disclosed in the α chain variable region of TCR for stability Introducing artificial interchain disulfide bond between β chain constant region can be such that the stability of TCR significantly improves.Therefore, height parent of the invention Artificial interchain disulfide bond can also be contained between the α chain variable region and β chain constant region of power TCR.Specifically, in the α of the TCR The cysteine residues of artificial interchain disulfide bond are formed between chain variable region and β chain constant region instead of the 46th ammonia of TRAV 60th amino acids of base acid and TRBC1*01 or TRBC2*01 exons 1；The 47th amino acids and TRBC1*01 of TRAV or 61 amino acids of TRBC2*01 exons 1；The of the 46th amino acids of TRAV and TRBC1*01 or TRBC2*01 exons 1 61 amino acids；Or TRAV the 47th amino acids and TRBC1*01 or TRBC2*01 exons 1 the 60th amino acids.It is preferred that Ground, such TCR may include all or part of TCR α chain of (I) in addition to its transmembrane domain, and (II) removes its cross-film knot All or part of TCR β chain other than structure domain, wherein (I) and (II) variable domain comprising TCR chain and at least part is constant Domain, α chain and β chain form heterodimer.It is highly preferred that such TCR may include α chain variable domain and β chain variable domain and All or part of β chain constant domain in addition to transmembrane domain, but it does not contain α chain constant domain, the α chain variable domain of the TCR Heterodimer is formed with β chain.

For stability, on the other hand, TCR of the present invention further includes the TCR to mutate in its hydrophobic core region, this The mutation of a little hydrophobic core regions is preferably capable making the stability-enhanced mutation of TCR of the present invention, such as in Publication No. WO2014/ Described in 206304 patent document.Such TCR can mutate in its following hydrophobic core position of variable domain: (α and/or β Chain) variable region amino acid the 11st, 13,19,21,53,76,89,91,94 and/or α chain J gene (TRAJ) small peptide amino acid position It is 2nd, 4,6 reciprocal to set the 3rd, 5,7 and/or β chain J gene (TRBJ) small peptide amino acid position reciprocal, wherein amino acid sequence Position Number press the Position Number listed in international immunogenetics information system (IMGT).On as known to those skilled in the art International immunogenetics information system is stated, and position of the amino acid residue of different TCR in IMGT can be obtained according to the database Set number.

More specifically, the TCR that hydrophobic core region mutates in the present invention can be by the α of a flexible peptide chain link TCR The single-stranded TCR of high stability constituted with the variable domain of β chain.The CDR region of the variable region TCR determines itself and small peptide-HLA compound Between affinity, the mutation of hydrophobic core can make TCR more stable, but will not influence it between small peptide-HLA compound Affinity.It should be noted that flexible peptide chain can be the peptide chain of any suitable connection TCR α and β chain variable domain in the present invention.This hair The template strand for screening high-affinity TCR constructed in bright embodiment 1 is the above-mentioned high stability containing the mutation of hydrophobic core Single-stranded TCR.Using the TCR of high stability, can more easily assess between TCR and ILSPFLPLL-HLA-A2 compound Affinity.

The α chain variable domain of single-stranded template TCR and the CDR region of β chain variable domain are identical with the CDR region of wild type TCR. That is 3 CDR of α chain variable domain are respectively CDR1 α: DRGSQS, and CDR2 α: IYSNGD, CDR3 α: AVNLYAGNMLT and β chain are variable 3 CDR in domain are respectively CDR1 β: SGHVS, CDR2 β: FQNEAQ, CDR3 β: ASSSDFGNQPQH.The ammonia of single-stranded template TCR Base acid sequence (SEQ ID NO:1) and nucleotide sequence (SEQ ID NO:47) difference are as seen in figure la and lb.It is filtered out with this There is the single-stranded TCR of high-affinity being made of α chain variable domain and β chain variable domain to ILSPFLPLL-HLA A2 compound.

3 CDR, that is, CDR1, the CDR2 of single-stranded template TCR α chain variable domain SEQ ID NO:2 and CDR3 difference in the present invention Positioned at 27-32,50-55 and 90-100 of SEQ ID NO:2.Accordingly, numbering amino acid residues use SEQ It is numbered shown in ID NO:2,51Y is the 2nd Y of CDR2 α, and 52S is the 3rd S of CDR2 α, and 53N is the 4 of CDR2 α Position N, 54G is the 5th G of CDR2 α, and 55D is the 6th D of CDR2 α, and 91V is the 2nd V of CDR3 α, and 96G is The 7th G of CDR3 α, 97N are the 8th N of CDR3 α, and 98M is the 9th M of CDR3 α, and 99L is the 10th of CDR3 α L, 100T are the 11st T of CDR3 α.

Similarly, the present invention in single-stranded template TCR β chain variable domain SEQ ID NO:3 3 CDR, that is, CDR1, CDR2 and CDR3 It is located at 27-31,49-54 and 93-104 of SEQ ID NO:3.Therefore, numbering amino acid residues use It is numbered shown in SEQ ID NO:3,27S is the 1st S of CDR1 β, and 28G is the 2nd G of CDR1 β, and 29H is CDR1 β The 3rd H, 30V is the 4th V of CDR1 β, and 31S is the 5th S of CDR1 β, and 96S is the 4th S of CDR3 β, and 97D is It is the 6th F of CDR3 β for the 5th D of CDR3 β, 98F, 99G is the 7th G of CDR3 β, and 100N is the 8 of CDR3 β Position N, 101Q is the 9th Q of CDR3 β.

The acquisition of α β heterodimer to ILSPFLPLL-HLA-A2 compound with high-affinity of the invention is logical The CDR region for crossing α and β the chain variable domain of the single-stranded TCR of the high-affinity that will be filtered out is transferred to wild type TCR α chain variable domain (SEQ ID NO:24) it is obtained with the corresponding position of β chain variable domain (SEQ ID NO:25).

In some embodiments of the invention, it is numbered using shown in SEQ ID NO:24, the α chain of TCR of the present invention is variable The hydrophobic core amino acid residue 19A in domain (i.e. the α chain variable region listed in IMGT the 19th), (i.e. the α chain listed in IMGT can by 21L Become the 21st, area), 39Y (i.e. the α chain variable region listed in IMGT the 39th), (the i.e. α chain variable region listed in IMGT the 40S 40), 79S (i.e. the α chain variable region listed in IMGT the 79th) and 88L (i.e. the α chain variable region listed in IMGT the 88th) In have one or more mutate and/or using number shown in SEQ ID NO:25, the hydrophobic core of the TCR β chain variable domain Amino acid residue 11K (i.e. the β chain variable region listed in IMGT the 11st), (the i.e. β chain variable region the 13rd listed in IMGT 13A Position), 36Q (i.e. the β chain variable region listed in IMGT the 36th), 38A (i.e. the β chain variable region listed in IMGT the 38th), 39L (i.e. the β chain variable region listed in IMGT the 39th), 43P (i.e. the β chain variable region listed in IMGT the 43rd), 82T (i.e. IMGT In the β chain variable region the 82nd listed), 84Q (i.e. the β chain variable region listed in IMGT the 84th), 91L (i.e. list in IMGT β chain variable region the 91st) and 113I (i.e. the β chain variable region listed in IMGT the 113rd) in have it is one or more occur it is prominent Become.

More specifically, being numbered in some currently preferred embodiments of the present invention using shown in SEQ ID NO:24, the present invention The hydrophobic core of α chain variable domain includes one or more of amino acid residue 19V, 21I, 39D, 40P, 79V or 88F and/or uses Shown in SEQ ID NO:25 number, the hydrophobic core of TCR β variable domain include amino acid residue 11L, 13V, 36R, 38D, 39P, One or more of 43L, 82V, 84P, 91F or 113V.More specifically, the mutant form packet of the hydrophobic core of TCR α variable domain Include one group in A19V, L21I, Y39D, S40P, S79V or L88F or several groups；The mutant form of the hydrophobic core of TCR β variable domain Including one group or several groups in K11L, A13V, Q36R, A38D, L39P, P43L, T82V, Q84P, L91F or I113V.

High-affinity TCR of the invention also include α chain variable domain amino acid sequence SEQ ID NO:5,6,7,8,9,10, 11, one of 12,13,14,15,16,17,18,19,20,21,22 and 23.Therefore, the above-mentioned high stability as template strand is single-stranded TCR β chain variable domain (SEQ ID NO:3) can with amino acid sequence be SEQ ID NO:5,6,7,8,9,10,11,12,13,14, 15,16,17,18,19,20,21,22 or 23 TCR α chain variable domain combines to form the single chain TCR molecules.It is high in the present invention The α chain variable domain of affinity single chain TCR molecules and the amino acid sequence of β chain variable domain preferably are selected from the following table 2:

Table 2

TCR of the invention can also be provided in the form of multivalence complex.Multivalent TCR complex of the invention include two, Three, four or more TCR of the present invention are combined and the polymer that is formed, can such as be generated with four dimerization domains of p53 The compound that the tetramer or multiple TCR of the present invention are formed in conjunction with another molecule.TCR compound of the invention can be used for body Outer or tracking in vivo or targeting present the cell of specific antigen, it can also be used to which generating has other multivalence TCR of such application multiple Close the intermediate of object.

TCR of the invention can be used alone, can also with conjugate with covalent or other modes in conjunction with, preferably with covalently side Formula combines.The conjugate includes that detectable marker (for diagnostic purpose, presents wherein the TCR is used to detect The presence of the cell of ILSPFLPLL-HLA-A2 compound), therapeutic agent, PK (protein kinase) modified part or any the above The combination of substance combines or coupling.

Detectable marker for diagnostic purposes includes but is not limited to: fluorescence or luminous marker, radioactively labelled substance, MRI (magnetic resonance imaging) or CT (x-ray tomography of electronic computer) contrast agent can generate detectable product Enzyme.

Can in conjunction with TCR of the present invention or coupling therapeutic agent include but is not limited to: 1. radionuclides (Koppe etc., 2005, (Cancer metastasis reviews) 24,539 is commented in metastasis of cancer)；2. biology poison (Chaudhary etc., 1989, Natural (Nature) 339,394；Epel etc., 2002, Cancer Immunol and immunization therapy (Cancer Immunology and Immunotherapy) 51,565)；3. cell factor such as IL-2 etc. (Gillies etc., 1992, National Academy of Sciences proceeding (PNAS) 89,1428；Card etc., 2004, Cancer Immunol and immunization therapy (Cancer Immunology and Immunotherapy) 53,345；Halin etc., 2003, cancer research (Cancer Research) 63,3202)；4. antibody Fc Segment (Mosquera etc., 2005, Journal of Immunology (The Journal Of Immunology) 174,4381)；5. antibody ScFv segment (Zhu etc., 1995, cancer International Periodicals (International Journal of Cancer) 62,319)；6. gold medal (Lapotko etc., 2005, cancer communicates (Cancer letters) 239,36 to nano particle/nanometer rods；Huang etc., 2006, beauty Chemical Society, state magazine (Journal of the American Chemical Society) 128,2115)；7. virion (Peng etc., 2004, gene therapy (Gene therapy) 11,1234)；8. liposome (Mamot etc., 2005, cancer research (Cancer research) 65,11631)；9. magnetic nanosphere；10. pro-drug activation enzymes are (for example, DT- diaphorase (DTD) or connection Phenyl hydrolase-sample protein (BPHL))；11. chemotherapeutics (for example, cis-platinum) or any type of nano particle etc..

Antibody or its segment in conjunction with TCR of the present invention include that anti-T cell or NK- cell determine antibody, such as anti-CD3 or Anti- CD28 or anti-CD16 antibody, the combination of above-mentioned antibody or its segment and TCR can pairing effect cell be oriented come it is more preferable Ground targets target cell.One preferred embodiment is the function of TCR of the present invention and anti-CD 3 antibodies or the anti-CD 3 antibodies Segment or variant combine.Specifically, the fusion molecule of TCR of the invention and AntiCD3 McAb single-chain antibody includes TCR α selected from the group below Chain variable domain amino acid sequence SEQ ID NO:2,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21, TCR β chain variable domain amino acid sequence shown in 22 or 23 and SEQ ID NO:3；Again specifically, TCR of the invention and AntiCD3 McAb list The fusion molecule of chain antibody include TCR α chain variable domain amino acid sequence SEQ ID NO:24 selected from the group below, 28,29,30,31, 32, TCR β chain variable domain shown in 33,34,35,36,37,38,39,40,41,42,43,44,45 or 46 and SEQ ID NO:25 Amino acid sequence.

The invention further relates to the nucleic acid molecules for encoding TCR of the present invention.Nucleic acid molecules of the invention can be DNA form or Rna form.DNA can be coding strand or noncoding strand.For example, the nucleic acid sequence of coding TCR of the present invention can be attached with the present invention Nucleic acid sequence shown in figure is identical or the variant of degeneracy.The meaning for illustrating " variant of degeneracy ", such as this paper institute With, " variant of degeneracy " refer in the present invention coding have SEQ ID NO:1 protein sequence, but with SEQ ID NO:47 The differentiated nucleic acid sequence of sequence.

Nucleic acid molecules full length sequence or its segment of the invention usually can with but be not limited to PCR amplification method, recombination method or Artificial synthesized method obtains.At present, it is already possible to obtain encoding completely by chemical synthesis TCR of the present invention (or its segment, Or derivatives thereof) DNA sequence dna.Then the DNA sequence dna can be introduced various existing DNA moleculars as known in the art (or Such as carrier) and cell in.

The present invention also relates to the carriers comprising nucleic acid molecules of the invention, and are passed through with carrier of the invention or coded sequence The host cell that genetic engineering generates.

The invention also includes the separation cells for expressing TCR of the present invention, especially T cell.There are many methods to be suitable for volume The DNA or RNA of the high-affinity TCR of code book invention carries out T cell transfection (e.g., the such as Robbins, (2008) J.Immunol.180:6116-6131).The T cell for expressing high-affinity TCR of the present invention can be used for adoptive immunotherapy.This Field technical staff understand that many appropriate methods (e.g., the such as Rosenberg, (2008) Nat for carrying out adoptive treatment Rev Cancer8 (4): 299-308).

The present invention also provides a kind of pharmaceutical composition, described pharmaceutical composition contains pharmaceutically acceptable carrier and sheet It invents TCR or TCR compound of the present invention or presents the cell of TCR of the present invention.

The present invention also provides a kind of methods for treating disease, including apply suitable present invention to object in need for the treatment of The cell or pharmaceutical composition of the invention of TCR or TCR compound of the present invention or presentation TCR of the present invention.

It should be understood that amino acid name herein is identified using international single English alphabet, amino corresponding thereto Sour three English alphabet of title is write a Chinese character in simplified form: Ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly(G)、His(H)、Ile(I)、Leu(L)、Lys(K)、Met(M)、Phe(F)、Pro(P)、Ser(S)、Thr(T)、Trp(W)、 Tyr(Y),Val(V)；In the present invention, Pro60 or 60P indicate the 60th proline.In addition, heretofore described mutation The form of presentation of the concrete form K that such as " K52A " represents the 52nd is replaced by A, and similarly, " K52A/R/M/T " represents the 52nd K Replaced or replaced or replaced or replaced by T by M by R by A.Other and so on.

In the art, when being substituted with similar nature or similar amino acid, the function of protein is not usually changed Energy.The structure and function of protein will not be changed by adding one or several amino acid generally also in C-terminal and/or N-terminal.Cause This, TCR of the present invention further includes at most 5 of TCR of the present invention, and preferably at most 3, more preferably at most 2, most preferably 1 ammonia Base acid (is especially located at the amino acid except CDR region), is replaced by amino acid with similar or analogous properties, and still be able to keep Its functional TCR.

The invention also includes the TCR after slightly modifying TCR of the present invention.Modify (not changing primary structure usually) form packet It includes: the chemical derivative form of TCR of the present invention such as acetylation or carboxylated.Modification further includes glycosylation, as those are in TCR of the present invention Synthesis and processing in or further processing step in carry out it is glycosylation modified and generate TCR.This modification can pass through by TCR, which is exposed to, to carry out glycosylated enzyme (glycosylase or deglycosylation enzyme of such as mammal) and completes.Modified forms also wrap Include the sequence with phosphorylated amino acid residue (such as phosphotyrosine, phosphoserine, phosphothreonine).It further include being modified To improve its anti-proteolytic properties or optimize the TCR of solubility property.

TCR, TCR compound of the invention or the T cell of TCR of the present invention transfection can be together with pharmaceutically acceptable carriers It is provided in pharmaceutical composition.TCR, multivalent TCR complex or cell of the invention is usually as the one of sterile pharmaceutical composition Part provides, and the composition generally includes pharmaceutically acceptable carrier.The pharmaceutical composition can be any suitable shape Formula (depending on giving the required method of patient).Unit dosage forms offer can be used in it, usually provides, can make in the container of sealing It is provided for a part of kit.Such kit (but nonessential) includes operation instructions.It may include multiple units Dosage form.

In addition, TCR of the invention can be applied alone, in conjunction with other therapeutic agents or use can also be coupled together (as prepared In the same pharmaceutical composition).

Pharmaceutical composition can also contain pharmaceutically acceptable carrier.Term " pharmaceutically acceptable carrier " refers to for controlling Treat the carrier of agent administration.The term refers to medicament carriers some in this way: themselves not inducing generated to the composition is received The harmful antibody of body, and there is no excessive toxicity after being administered.These carriers are well known to those of ordinary skill in the art.In thunder It can in bright pharmaceutical science (Remington's Pharmaceutical Sciences (Mack Pub.Co., N.J.1991)) Find discussing fully about pharmaceutically acceptable excipient.This kind of carrier include (but being not limited to): salt water, buffer, Glucose, water, glycerol, ethyl alcohol, adjuvant, and combinations thereof.

Acceptable carrier can contain liquid in therapeutic composition Chinese pharmacology, such as water, salt water, glycerol and ethyl alcohol.In addition, There is likely to be complementary substances, such as wetting agent or emulsifier, pH buffer substance in these carriers.

In general, therapeutic composition can be made to injectable agent, such as liquid solution or suspension；It may also be fabricated which before the injection It is suitble in supplying solution or suspension, the solid form of liquid-carrier.

Once being made into the composition of the present invention, it can be administered by conventional route, including (but and it is unlimited In): intraocular, intramuscular, intravenous, subcutaneous, intradermal or local administration, preferably parenteral includes subcutaneous, intramuscular or vein It is interior.Object to be prevented or to be treated can be animal；Especially people.

When pharmaceutical composition of the present invention is used for actual treatment, various different dosage forms can be used according to service condition Pharmaceutical composition.Preferably, what can be enumerated has injection, oral agents etc..

These pharmaceutical compositions can be prepared by mixing, diluting or dissolving according to conventional methods, and add once in a while Add suitable medicated premix, such as excipient, disintegrating agent, adhesive, lubricant, diluent, buffer, isotonic agent (isotonicities), preservative, wetting agent, emulsifier, dispersing agent, stabilizer and cosolvent, and the process for preparation can root It is carried out with usual way according to dosage form.

Pharmaceutical composition of the invention can be administered with sustained release formulation.For example, TCR of the present invention can be impregnated in be sustained and gather It closes in the pill or micro-capsule that object is carrier, the pill or micro-capsule is then implanted into tissue to be treated by operation.As sustained release The example of polymer, what can be enumerated has thylene-vinylacetate copolymer, poly- hydroxyl-metacrylate (polyhydrometaacrylate), polyacrylamide, polyvinylpyrrolidone, methylcellulose, lactic acid polymer, lactic acid- Ethanol copolymer etc., preferably exemplifiable is that biodegradable polymer such as lactic acid polymer and lactic acid-ethanol are total Polymers.

When pharmaceutical composition of the present invention is used for actual treatment, compound as the TCR or TCR of the present invention of active constituent Object or the cell for presenting TCR of the present invention, can be according to the weight, age, gender, degree of symptoms of each patient to be treated and reasonable Ground is determined, finally determines reasonable dosage by doctor.

Main advantages of the present invention are:

(1) present invention is had selected as stencil screen to the ILSPFLPLL-HLA- using the single chain TCR molecules of hydrophobic core mutation A2 compound has the TCR of high-affinity.

(2) TCR of the invention is wild to the affinity of the ILSPFLPLL-HLA-A2 compound and/or in conjunction with half-life period At least 1.3 times of raw type TCR.

(3) affinity and/or combination of the TCR of high-affinity of the invention to the ILSPFLPLL-HLA-A2 compound Half-life period can achieve 1.3-24 times of wild type TCR.

(4) the effector cell TCR-T of the TCR transduction of high-affinity of the invention is directed to T2 cell loading small peptide (ILSPFLPLL) reaction EC50 is lower than the EC50 of wild type TCR-T, at least has dropped an order of magnitude.

(5) the effector cell TCR-T of the TCR transduction of high-affinity of the invention is directed to expression specificity antigen (ILSPFLPLL) fragmentation effect of tumor cells of hepatocellular carcinoma is more preferable than wild type TCR-T.

Following specific embodiment, the present invention is further explained.It should be understood that these embodiments be merely to illustrate the present invention and It is not used in and limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition, Such as (Sambrook and Russell et al., molecular cloning: laboratory manual (Molecular Cloning-A Laboratory Manual) (third edition) (2001) CSHL publishing house) described in condition, or according to the normal condition proposed by manufacturer.Unless In addition illustrate, otherwise percentage and number are calculated by weight.

Material and method

Experimental material used in the embodiment of the present invention can obtain unless otherwise specified from commercially available channel, wherein E.coli DH5 α is purchased from purchased from Tiangen, E.coli BL21 (DE3) purchased from Tiangen, E.coli Tuner (DE3) Novagen, plasmid pET28a are purchased from Novagen.

The generation of the single-stranded TCR template strand of stability of the hydrophobic core of embodiment 1 mutation

The present invention is constructed using the method for rite-directed mutagenesis according to patent document WO2014/206304 with one Flexible small peptide (linker) connects the stability single chain TCR molecules that TCR α is constituted with β chain variable domain, amino acid and DNA sequence Column are respectively SEQ ID NO:1 and SEQ ID NO:47, as illustrated in figs. 1A and ib.And using the single chain TCR molecules as template into The screening of row high-affinity TCR molecule.The α variable domain (SEQ ID NO:2) and β variable domain (SEQ ID NO:3) of the template strand Amino acid sequence as shown in figures 2 a and 2b；Its corresponding DNA sequence dna is respectively SEQ ID NO:48 and 49, such as Fig. 3 a and 3b institute Show；The amino acid sequence and DNA sequence dna of flexible small peptide (linker) are respectively SEQ ID NO:4 and 50, as shown in Figs. 4a and 4b.

The target gene of template strand will be carried through I double digestion of Nco I and Not, and by Nco I and I double digestion of Not The connection of pET28a carrier.Connection product is converted to E.coli DH5 α, is coated with the LB plate containing kanamycins, 37 DEG C of inversion cultures Overnight, picking positive colony carries out PCR screening, is sequenced to positive recombinant, determines that sequence correctly extracts recombinant plasmid afterwards Conversion is to E.coli BL21 (DE3), for expressing.

Expression, renaturation and the purifying of the single-stranded TCR of stability constructed in 2 embodiment 1 of embodiment

BL21 (DE 3) bacterium colony containing recombinant plasmid pET28a- template strand prepared in embodiment 1 is all inoculated in In LB culture medium containing kanamycin, 37 DEG C of cultures to OD₆₀₀For 0.6-0.8, it is added IPTG to final concentration of 0.5mM, 37 DEG C Continue to cultivate 4h.5000rpm is centrifuged 15min and harvests cell precipitate, is cracked with Bugbuster Master Mix (Merck) thin Born of the same parents' sediment, 6000rpm are centrifuged 15min and recycle inclusion body, then are washed with Bugbuster (Merck) broken to remove cell Piece and membrane component, 6000rpm are centrifuged 15min, collect inclusion body.By solubilization of inclusion bodies in buffer (20mM Tris-HCl pH 8.0,8M urea) in, high speed centrifugation removes insoluble matter, is dispensed after supernatant BCA standard measure, is saved backup in -80 DEG C.

In the single-stranded TCR inclusion body protein dissolved to 5mg, 2.5mL buffer (6M Gua-HCl, 50mM Tris- is added HCl pH 8.1,100mM NaCl, 10mM EDTA), add DTT to final concentration of 10mM, 37 DEG C of processing 30min.With injection Device is to 125mL renaturation buffer (100mM Tris-HCl pH 8.1,0.4M L-arginine, 5M urea, 2mM EDTA, 6.5mM β-mercapthoethylamine, 1.87mM Cystamine) in treated single-stranded TCR, 4 DEG C of stirrings are added dropwise Then renaturation solution is packed into the cellulose membrane bag filter that interception is 4kDa by 10min, bag filter is placed in the water of 1L pre-cooling, and 4 DEG C It is slowly stirred overnight.After 17 hours, by dialyzate change into 1L pre-cooling buffer (20mM Tris-HCl pH 8.0), 4 DEG C after Continuous dialysis 8h, then changes dialyzate into identical fresh buffer and continues dialysed overnight.After 17 hours, sample is filtered through 0.45 μm Film filtering, by anion-exchange column (HiTrap Q HP, GE Healthcare) after vacuum outgas, with 20mM Tris-HCl The 0-1M NaCl linear gradient elution liquid purifying protein that pH 8.0 is prepared, the elution fraction of collection carry out SDS-PAGE analysis, packet It is further carried out with solvent resistant column (Superdex 7510/300, GE Healthcare) after component concentration containing single-stranded TCR Purifying, target components also carry out SDS-PAGE analysis.

Elution fraction for BIAcore analysis further uses gel filtration to test its purity.Condition are as follows: chromatographic column Agilent Bio SEC-3 (7.8 × 300mm of 300A, φ), mobile phase be 150mM phosphate buffer, flow velocity 0.5mL/min, 25 DEG C of column temperature, ultraviolet detection wavelength 214nm.

Embodiment 3 combines characterization

BIAcore analysis

Use the combination of BIAcore T200 real-time analyzer detection TCR molecule and ILSPFLPLL-HLA-A2 compound Activity.Coupling buffer (10mM sodium-acetate buffer, pH 4.77) is added in the antibody (GenScript) of anti-Streptavidin, Then antibody is flowed through to the CM5 chip activated in advance with EDC and NHS, so that antibody is fixed on chip surface, finally use ethanol amine Hydrochloric acid solution close unreacted activating surface, complete coupling process, coupling horizontal about 15,000RU.

So that the Streptavidin of low concentration is flowed through the chip surface of coated antibody, then answers ILSPFLPLL-HLA-A2 It closes logistics and crosses sense channel, another channel is flowed through as reference channel, then by the biotin of 0.05mM with the flow velocity of 10 μ L/min Chip 2min closes the remaining binding site of Streptavidin.Its affinity is measured using single cycle dynamic analysis method, it will TCR HEPES-EP buffer (10mM HEPES, 150mM NaCl, 3mM EDTA, 0.005%P20, pH 7.4) is diluted to several A different concentration flows successively through chip surface with the flow velocity of 30 μ L/min, and the binding time of each sample introduction is 120s, finally It is allowed to dissociate 600s after single injected sampling.Each round uses the 10mM Gly-HCl regeneration chip of pH 1.75 after measuring.Benefit With BIAcore Evaluation software computational dynamics parameter.

The preparation process of above-mentioned ILSPFLPLL-HLA-A2 compound is as follows:

A. it purifies

The E.coli bacterium solution for collecting 100ml inducing expression heavy chain or light chain uses 10ml after 4 DEG C of 8000g are centrifuged 10min PBS washing thalline is primary, violent with 5ml BugBuster Master Mix Extraction Reagents (Merck) later Thallus is resuspended in concussion, and rotates in room temperature and be incubated for 20min, and later in 4 DEG C, 6000g is centrifuged 15min, discards supernatant, collection is forgiven Body.

Above-mentioned inclusion body is resuspended in 5ml BugBuster Master Mix, room temperature rotation is incubated for 5min；Add 30ml The BugBuster of 10 times of dilution is mixed, and 4 DEG C of 6000g are centrifuged 15min；It discards supernatant, 30ml is added to dilute 10 times of BugBuster Inclusion body is resuspended, mixes, 4 DEG C of 6000g are centrifuged 15min, are repeated twice, and add 30ml 20mM Tris-HCl pH 8.0 that packet is resuspended Contain body, mix, 4 DEG C of 6000g are centrifuged 15min, finally dissolve inclusion body, SDS-PAGE detection with 20mM Tris-HCl 8M urea Inclusion body purity, BCA kit survey concentration.

B. renaturation

The small peptide ILSPFLPLL (Nanjing Genscript Biotechnology Co., Ltd.) of synthesis is dissolved in DMSO to 20mg/ml Concentration.The inclusion body of light chain and heavy chain 8M urea, 20mM Tris pH 8.0,10mM DTT dissolve, and are added before renaturation 3M guanidine hydrochloride, 10mM sodium acetate, 10mM EDTA are further denaturalized.Renaturation is added with 25mg/L (final concentration) in ILSPFLPLL peptide Buffer (0.4M L-arginine, 100mM Tris pH 8.3,2mM EDTA, 0.5mM oxidative glutathione, 5mM reduced form Glutathione, 0.2mM PMSF, are cooled to 4 DEG C), then sequentially add 20mg/L light chain and 90mg/L heavy chain (final concentration, Heavy chain is added in three times, and 8h/ times), renaturation carries out at least 3 days at 4 DEG C to completion, and can SDS-PAGE detection renaturation success.

C. it is purified after renaturation

Make dialysis with the 20mM Tris pH 8.0 of 10 volumes to replace renaturation buffer, at least replacement buffer comes twice Sufficiently reduce the ionic strength of solution.With 0.45 μm of cellulose acetate sheets filtration protein solution after dialysis, it is then loaded into On HiTrap Q HP (GE General Electric Co. Limited) anion-exchange column (5ml bed volume).Instrument (the general electricity of GE is purified using Akta Gas company), the 0-400mM NaCl linear gradient liquid that 20mM Tris pH 8.0 is prepared elutes albumen, and pMHC is about in 250mM It is eluted at NaCl, collects all peak components, SDS-PAGE detects purity.

D. biotinylation

It with Millipore super filter tube by the pMHC molecular concentration of purifying, while being 20mM Tris pH by buffer exchange 8.0, biotinylation reagent 0.05M Bicine pH 8.3,10mM ATP, 10mM MgOAc, 50 μM of D- is then added Biotin, 100 μ g/ml BirA enzymes (GST-BirA), incubation at room temperature mixture are stayed overnight, and whether SDS-PAGE detects biotinylation Completely.

E. the compound after purifying biological element

PMHC molecular concentration after being marked biotinylation with Millipore super filter tube is to 1ml, using gel permeation chromatography The pMHC of purifying biological element, purifies instrument (GE General Electric Co. Limited) using Akta, pre-equilibrates HiPrep with filtered PBS^TM 16/60S200HR column (GE General Electric Co. Limited), load 1ml concentrated biotinylation pMHC molecule, then with PBS with 1ml/ The elution of min flow velocity.Biotinylated pMHC molecule occurs in about 55ml as unimodal elution.Merge the group containing protein Point, it is concentrated with Millipore super filter tube, BCA method (Thermo) measures protein concentration, and protease inhibitors cocktail is added (Roche) packing of biotinylated pMHC molecule is stored in -80 DEG C.

The generation of the single-stranded TCR of 4 high-affinity of embodiment

Display technique of bacteriophage is a kind of means for generating TCR high-affinity Mutant libraries to screen high-affinity variant. The TCR phage display of Li et al. ((2005) Nature Biotech 23 (3): 349-354) description and screening technique are applied to Single-stranded TCR template in embodiment 1.The library of high-affinity TCR is established by being mutated the CDR region of the template strand and is washed in a pan Choosing.Those skilled in the art can be obtained by reading above-mentioned document and described build library and screening technique.I.e. by using with institute The primer of the one or more codons variation needed is realized to as the plasmid containing related DNA of template.By a few wheel elutriations Phage library afterwards is and corresponding antigens have specific binding, therefrom picking monoclonal, and carries out sequence analysis.

Using the phase interaction of the analysis of BIAcore method TCR molecule and ILSPFLPLL-HLA-A2 compound in embodiment 3 With having filtered out affinity and/or having combined half-life period is at least 2 times of the high-affinity TCR of wild type TCR, that is, is filtered out The Dissociation equilibrium constant K of high-affinity TCR combination ILSPFLPLL-HLA-A2 compound_DIt is combined less than or equal to wild type TCR The Dissociation equilibrium constant K of ILSPFLPLL-HLA-A2 compound_DHalf, as a result as shown in table 3 below.Utilize the above method Detect the K of reference TCR and the interaction of ILSPFLPLL-HLA-A2 compound_DValue is 3.4 μM, and Curves of Interaction is as schemed Shown in 9, i.e. the K of wild type TCR and the interaction of ILSPFLPLL-HLA-A2 compound_DValue is also 3.4 μM.

Specifically, it is numbered using shown in SEQ ID NO:24, the α chain variable domain of these high-affinities TCR mutant Amino acid in following one or more sites mutates: 92N, 93L, 94Y, 95A or 96G.

More specifically, numbering using shown in SEQ ID NO:24, the α chain variable domain of these high-affinities TCR includes choosing From one or more amino acid residue 92Q or 92A of the following group；93D, 93E, 93G, 93S or 93H；94P, 94Q, 94S or 94G； 95S, 95T, 95W or 95D；96R, 96K, 96M, 96Q, 96N, 96T, 96S or 96H.

The single-stranded TCR of high-affinity α chain variable domain (SEQ ID NO:5,6,7,8,9,10,11,12,13,14,15,16, 17,18,19,20,21,22,23,24,25 and specific amino acid sequence 26) respectively as shown in Fig. 5 a-s.

Table 3

Through detecting, the affinity and/or combination half-life period of TCR α chain variable domain and TCR β chain variable domain reach in upper table At least 2 times of wild type TCR.

The generation of the 5 heterogeneous dimerization TCR of high-affinity α β of embodiment

The CDR region mutation of the single-stranded TCR of the high-affinity screened in embodiment 4 is introduced into the heterogeneous dimerization TCR's of α β In the corresponding site of variable domain, and detect by BIAcore the affinity of itself and ILSPFLPLL-HLA-A2 compound.It is above-mentioned The method that the introducing of CDR region high-affinity catastrophe point uses rite-directed mutagenesis well known to those skilled in the art.Above-mentioned wild type TCR α chain and β chain variable domain amino acid sequence respectively as shown in Fig. 6 a (SEQ ID NO:24) and 6b (SEQ ID NO:25).

It should be noted that obtain more stable sTCR, more easily to assess TCR and ILSPFLPLL-HLA Binding affinity between A2 compound and/or half-life period is combined, the heterogeneous dimerization TCR of α β can be in the constant region of α and β chain It introduces a cysteine residues respectively to form the TCR of artificial interchain disulfide bond, it is residual to introduce cysteine in the present embodiment The amino acid sequence of TCR α and β chain draws respectively as shown in Fig. 7 a (SEQ ID NO:26) and Fig. 7 b (SEQ ID NO:27) after base The cysteine residues entered are indicated with overstriking letter.

Pass through " Molecular Cloning: A Laboratory room handbook " (Molecular Cloning a Laboratory Manual) (third Version, Sambrook and Russell) described in standard method by the extracellular sequence gene of TCR α and β chain to be expressed through synthesizing After be inserted respectively into expression vector pET28a+ (Novagene), the cloning site of upstream and downstream is NcoI and NotI respectively.CDR region Mutation pass through over-lap PCR well known to those skilled in the art (overlap PCR) introduce.Insert Fragment is by sequencing confirmation nothing Accidentally.

Expression, renaturation and the purifying of the heterogeneous dimerization TCR of 6 α β of embodiment

The expression vector of TCR α and β chain is converted by chemical transformation respectively and enters expression bacterium BL21 (DE3), bacterium It is grown with LB culture solution, in OD₆₀₀It is induced when=0.6 with final concentration 0.5mM IPTG, the packet formed after α the and β chain expression of TCR Contain body to extract by BugBuster Mix (Novagene), and through the repeated multiple times washing of BugBuster solution, forgives Body is finally dissolved in 6M guanidine hydrochloride, 10mM dithiothreitol (DTT) (DTT), 10mM ethylenediamine tetra-acetic acid (EDTA), 20mM Tris (pH 8.1) in.

Dissolved TCR α and β chain are quickly mixed in 5M urea, 0.4M arginine, 20mM Tris with the mass ratio of 1:1 (pH 8.1), in 3.7mM cystamine, 6.6mM β-mercapoethylamine (4 DEG C), final concentration of 60mg/mL.Mixing Solution is placed in dialysis (4 DEG C) in the deionized water of 10 times of volumes afterwards, changes deionized water into buffer (20mM after 12 hours Tris, pH 8.0) continue at 4 DEG C of dialysis 12 hours.Solution after the completion of dialysis after 0.45 μM of membrane filtration, by yin from Sub- exchange column (HiTrap Q HP, 5ml, GE Healthcare) purifying.Eluting peak contains the successful α and β dimer of renaturation TCR is confirmed by SDS-PAGE glue.TCR then pass through gel permeation chromatography (HiPrep 16/60, Sephacryl S-100HR, GE Healthcare) it is further purified.TCR purity after purification is greater than 90% by SDS-PAGE measurement, and concentration is by BCA method It determines.

Embodiment 7BIAcore analyzes result

The heterogeneous dimerization TCR and ILSPFLPLL- of α β for introducing high-affinity CDR region is detected using method described in embodiment 3 The affinity of HLA-A2 compound.

The CDR region filtered out in the single-stranded TCR α of high-affinity and β chain is transferred to wild type TCR α chain variable domain SEQ respectively The corresponding position of ID NO:24 and β chain variable domain SEQ ID NO:25 forms the heterogeneous dimerization TCR of α β.Obtained new TCR α can Domain amino acid sequence, as shown in Fig. 8 a-s.Since the CDR region of TCR molecule determines the parent of itself and corresponding pMHC compound And power, so those skilled in the art are it is contemplated that the heterogeneous dimerization TCR of α β for introducing high-affinity catastrophe point also has pair The high-affinity of ILSPFLPLL-HLA-A2 compound.Using method construction of expression vector described in embodiment 5, embodiment is utilized The heterogeneous dimerization TCR of the α β that method described in 6 is mutated above-mentioned introducing high-affinity expressed, renaturation and purifying, is then utilized BIAcore T200 measures the affinity of itself and ILSPFLPLL-HLA-A2 compound, as shown in table 4 below.

Table 4

By upper table 4 it is found that the heterogeneous dimerization TCR of α β for introducing CDR region catastrophe point is maintained and answered ILSPFLPLL-HLA-A2 Close the high-affinity of object.The affinity of the heterogeneous dimerization TCR is parent of the wild type TCR to ILSPFLPLL-HLA-A2 compound With at least 1.3 times of power.

Embodiment 8 transfects the functional experiment of the effector cell of high-affinity TCR of the present invention

The present embodiment, which demonstrates, to be transfected the effector cell of high-affinity TCR of the present invention and can be supported the T2 of specific small peptide Cell-specific activation.The T2 cell-specific activation of non-specific small peptide or zero load cannot be supported.

Function and specificity of the high-affinity TCR of the present invention in cell are detected by ELISPOT experiment.Art technology The known method using ELISPOT experiment detection cell function of personnel.The present embodiment IFN-γ ELISPOT experiment is with from healthy will The PBL cell being separated in the blood of hope person through slow-virus transfection TCR as effect it is thin (label TCR1, TCR2, TCR3 respectively, TCR4, TCR5, TCR6, TCR7, TCR8, TCR9, TCR10, TCR11, TCR12, TCR13, TCR14, TCR15, TCR16, TCR17, TCR18, TCR19), control effector cell is marked as A6 (transfection HTLV-1Tax TCR), wild type effector cell's label For TCRWT.Experimental group is T2 Loading peptides pHBs (A0201HBs:ILSPFLPLL), and wherein small peptide concentration gradient is followed successively by 10^-13M, 10^-12M, 10^-11M, 10^-10M, 10^-9M, 10^-8M, 10^-7M, 10^-6M.Control group is T2 zero load or Loading peptides pNY- ESO-1 (A0201NY-ES0-1:SLLMWITQC), wherein small peptide concentration gradient is followed successively by 10^-12M, 10^-11M, 10^-10M, 10^-9M, 10^-8M, 10^-7M, 10^-6M。

Prepare ELISPOT plate first.ELISPOT plate Ethanol activation coating, 4 DEG C overnight.It tests the 1st day, goes to exchange By liquid, washing closing is incubated for two hours at room temperature, removes confining liquid, each component of test is added in the following order ELISPOT plate: culture medium adjusts effector cell to 2 X 10⁴A cells/ml, culture medium adjust T2 cell to 4 X 10⁵It is a Cells/ml, culture medium adjustment small peptide concentration are followed successively by 4 X 10^-13M, 4 X 10^-12M, 4 X 10^-11M, 4 X 10^-10M, 4 X 10^-9M, 4 X 10^-8M, 4 X 10^-7M, 4 X 10^-6M.50 μ L small peptides are respectively taken (wherein to be trained when T2 zero load with 50 μ L after mixing Support base replacement), 50 μ L T2 cell, 4 X 10⁵A cells/ml (i.e. 20,000 cells/well), 100 μ L effector cell, 2 X 10⁴A cells/ml (i.e. 2,000 cells/well) is added in corresponding aperture, and two multiple holes are arranged.Be incubated overnight (37 DEG C, 5% CO2).It tests the 2nd day, washing flat board simultaneously carries out secondary detection and colour developing, and dry plate recycles immunodotting plate reader (ELISPOT READER system；AID20 company) count the spot formed on film.Experimental result as shown in Figure 11 a-h, according to Secondary displaying high-affinity effector cell TCR6's, TCR10, TCR11, TCR12, TCR14, TCR15, TCR17, TCR19 is negative to T2 Carry the specific small peptide pHBs (A0201HBs:ILSPFLPLL) of concentration gradient and to the non-specific short of T2 loading concentrations gradient The IFN-γ of peptide pNY-ESO-1 (A0201NY-ES0-1:SLLMWITQC) discharges points.Experimental result as shown in Figure 12 a-h, according to Secondary displaying high-affinity effector cell TCR6's, TCR10, TCR11, TCR12, TCR14, TCR15, TCR17, TCR19 is empty to T2 IFN-γ release points and T2 loading concentrations are 10 when carrying (T2&non-peptide)^-6The specific small peptide pHBs of M (A0201HBs:ILSPFLPLL) IFN-γ release points when (T2&HBs-peptide or T2&pHBs).The high parent of the transfection present invention There is good specific activation to act on the effector cell of power TCR.

All references mentioned in the present invention is incorporated herein by reference, independent just as each document It is incorporated as with reference to such.In addition, it should also be understood that, after reading the above teachings of the present invention, those skilled in the art can To make various changes or modifications to the present invention, such equivalent forms equally fall within model defined by the application the appended claims It encloses.

Sequence table

<110>Chinese Academy of Sciences Guangzhou Institute of Biomedicine and Health

<120>high-affinity HBs T cell receptor

<130> P2018-0072

<160> 53

<170> PatentIn version 3.5

<210> 1

<211> 249

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 1

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Asn Leu Tyr Ala Gly

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro Gly

100 105 110

Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly

115 120 125

Gly Ser Glu Gly Gly Thr Gly Gly Ala Gly Val Ser Gln Ser Pro Arg

130 135 140

Tyr Leu Val Val Lys Arg Gly Gln Asp Val Ala Leu Arg Cys Asp Pro

145 150 155 160

Ile Ser Gly His Val Ser Leu Phe Trp Tyr Arg Gln Asp Pro Gly Gln

165 170 175

Gly Leu Glu Phe Leu Thr Tyr Phe Gln Asn Glu Ala Gln Leu Asp Lys

180 185 190

Ser Gly Leu Pro Ser Asp Arg Phe Phe Ala Glu Arg Pro Glu Gly Ser

195 200 205

Val Ser Thr Leu Lys Ile Gln Arg Val Gln Pro Glu Asp Ser Ala Val

210 215 220

Tyr Phe Cys Ala Ser Ser Ser Asp Phe Gly Asn Gln Pro Gln His Phe

225 230 235 240

Gly Asp Gly Thr Arg Leu Ser Val Leu

245

<210> 2

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 2

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Asn Leu Tyr Ala Gly

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 3

<211> 114

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 3

Gly Ala Gly Val Ser Gln Ser Pro Arg Tyr Leu Val Val Lys Arg Gly

1 5 10 15

Gln Asp Val Ala Leu Arg Cys Asp Pro Ile Ser Gly His Val Ser Leu

20 25 30

Phe Trp Tyr Arg Gln Asp Pro Gly Gln Gly Leu Glu Phe Leu Thr Tyr

35 40 45

Phe Gln Asn Glu Ala Gln Leu Asp Lys Ser Gly Leu Pro Ser Asp Arg

50 55 60

Phe Phe Ala Glu Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln

65 70 75 80

Arg Val Gln Pro Glu Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Ser

85 90 95

Asp Phe Gly Asn Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu Ser

100 105 110

Val Leu

<210> 4

<211> 24

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 4

Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly

1 5 10 15

Gly Gly Ser Glu Gly Gly Thr Gly

20

<210> 5

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 5

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 6

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 6

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Ala Asp Gln Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 7

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 7

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ser Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 8

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 8

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ser Met

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 9

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 9

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ser Gln

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 10

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 10

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Thr Asn

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 11

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 11

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Ser Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 12

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 12

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ala Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 13

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 13

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Glu Pro Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 14

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 14

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Thr Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 15

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 15

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Ala Gly Gly Trp Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 16

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 16

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Ser Pro Asp Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 17

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 17

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln His Pro Ala Thr

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 18

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 18

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Ala Asp Pro Ser Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 19

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 19

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Ala His Pro Ser Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 20

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 20

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Ser Pro Asp Gln

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 21

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 21

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ala Ser

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 22

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 22

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ser His

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 23

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 23

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Val Ser Ile Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Asp Pro Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Val Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Phe Cys Ala Val Gln Asp Pro Ser Thr

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 24

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 24

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Asn Leu Tyr Ala Gly

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 25

<211> 114

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 25

Gly Ala Gly Val Ser Gln Ser Pro Arg Tyr Lys Val Ala Lys Arg Gly

1 5 10 15

Gln Asp Val Ala Leu Arg Cys Asp Pro Ile Ser Gly His Val Ser Leu

20 25 30

Phe Trp Tyr Gln Gln Ala Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr

35 40 45

Phe Gln Asn Glu Ala Gln Leu Asp Lys Ser Gly Leu Pro Ser Asp Arg

50 55 60

Phe Phe Ala Glu Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln

65 70 75 80

Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Ser

85 90 95

Asp Phe Gly Asn Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu Ser

100 105 110

Ile Leu

<210> 26

<211> 205

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 26

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Asn Leu Tyr Ala Gly

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro His

100 105 110

Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser

115 120 125

Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn

130 135 140

Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys Val

145 150 155 160

Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp

165 170 175

Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile

180 185 190

Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser

195 200 205

<210> 27

<211> 244

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 27

Gly Ala Gly Val Ser Gln Ser Pro Arg Tyr Lys Val Ala Lys Arg Gly

1 5 10 15

Gln Asp Val Ala Leu Arg Cys Asp Pro Ile Ser Gly His Val Ser Leu

20 25 30

Phe Trp Tyr Gln Gln Ala Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr

35 40 45

Phe Gln Asn Glu Ala Gln Leu Asp Lys Ser Gly Leu Pro Ser Asp Arg

50 55 60

Phe Phe Ala Glu Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln

65 70 75 80

Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Ser

85 90 95

Asp Phe Gly Asn Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu Ser

100 105 110

Ile Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe

115 120 125

Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val

130 135 140

Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp

145 150 155 160

Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro

165 170 175

Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Ala Leu Ser Ser

180 185 190

Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asp Pro Arg Asn His Phe

195 200 205

Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr

210 215 220

Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp

225 230 235 240

Gly Arg Ala Asp

<210> 28

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 28

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 29

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 29

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Ala Asp Gln Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 30

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 30

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ser Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 31

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 31

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ser Met

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 32

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 32

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ser Gln

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 33

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 33

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Thr Asn

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 34

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 34

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Ser Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 35

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 35

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ala Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 36

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 36

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Glu Pro Ser Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 37

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 37

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Thr Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 38

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 38

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Ala Gly Gly Trp Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 39

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 39

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Ser Pro Asp Arg

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 40

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 40

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln His Pro Ala Thr

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 41

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 41

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Ala Asp Pro Ser Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 42

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 42

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Ala His Pro Ser Lys

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 43

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 43

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Ser Pro Asp Gln

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 44

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 44

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ala Ser

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 45

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 45

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ser His

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 46

<211> 111

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 46

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Gln Asp Pro Ser Thr

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro

100 105 110

<210> 47

<211> 747

<212> DNA

<213>artificial sequence (Artificial sequence)

<400> 47

cagaaagagg tggaacaaaa cagcggtccg ctgagcgtgc cggagggtgc gatcgttagc 60

attaactgca cctacagcga ccgtggcagc cagagcttct tttggtatcg tcaagatccg 120

ggtaaaagcc cggagctgat catgtttatt tacagcaacg gcgacaagga agatggtcgt 180

ttcaccgcgc agctgaacaa agcgagccaa tatgtgagcc tgctgatccg tgacgttcag 240

ccgagcgata gcgcgaccta cttttgcgcg gtgaacctgt atgcgggcaa catgctgacc 300

ttcggtggcg gtacccgtct gatggttaag ccgggcggtg gcagcgaggg tggcggtagc 360

gaaggcggtg gcagcgaggg tggcggtagc gaaggcggta ccggcggtgc gggtgttagc 420

cagagcccgc gttacctggt ggttaaacgt ggccaagacg tggcgctgcg ttgcgatccg 480

atcagcggtc acgttagcct gttttggtac cgtcaggacc cgggccaagg tctggagttc 540

ctgacctatt ttcagaacga agcgcaactg gacaagagcg gcctgccgag cgatcgtttc 600

tttgcggagc gtccggaagg tagcgtgagc accctgaaaa ttcagcgtgt gcaaccggaa 660

gatagcgcgg tttatttctg cgcgagcagc agcgactttg gtaaccagcc gcaacacttc 720

ggcgatggta cccgtctgag cgttctg 747

<210> 48

<211> 333

<212> DNA

<213>artificial sequence (Artificial sequence)

<400> 48

cagaaagagg tggaacaaaa cagcggtccg ctgagcgtgc cggagggtgc gatcgttagc 60

attaactgca cctacagcga ccgtggcagc cagagcttct tttggtatcg tcaagatccg 120

ggtaaaagcc cggagctgat catgtttatt tacagcaacg gcgacaagga agatggtcgt 180

ttcaccgcgc agctgaacaa agcgagccaa tatgtgagcc tgctgatccg tgacgttcag 240

ccgagcgata gcgcgaccta cttttgcgcg gtgaacctgt atgcgggcaa catgctgacc 300

ttcggtggcg gtacccgtct gatggttaag ccg 333

<210> 49

<211> 342

<212> DNA

<213>artificial sequence (Artificial sequence)

<400> 49

ggtgcgggtg ttagccagag cccgcgttac ctggtggtta aacgtggcca agacgtggcg 60

ctgcgttgcg atccgatcag cggtcacgtt agcctgtttt ggtaccgtca ggacccgggc 120

caaggtctgg agttcctgac ctattttcag aacgaagcgc aactggacaa gagcggcctg 180

ccgagcgatc gtttctttgc ggagcgtccg gaaggtagcg tgagcaccct gaaaattcag 240

cgtgtgcaac cggaagatag cgcggtttat ttctgcgcga gcagcagcga ctttggtaac 300

cagccgcaac acttcggcga tggtacccgt ctgagcgttc tg 342

<210> 50

<211> 72

<212> DNA

<213>artificial sequence (Artificial sequence)

<400> 50

ggcggtggca gcgagggtgg cggtagcgaa ggcggtggca gcgagggtgg cggtagcgaa 60

ggcggtaccg gc 72

<210> 51

<211> 205

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 51

Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly

1 5 10 15

Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser

20 25 30

Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met

35 40 45

Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln

50 55 60

Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln

65 70 75 80

Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Asn Leu Tyr Ala Gly

85 90 95

Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro His

100 105 110

Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser

115 120 125

Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn

130 135 140

Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr Val

145 150 155 160

Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp

165 170 175

Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile

180 185 190

Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser

195 200 205

<210> 52

<211> 244

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 52

Gly Ala Gly Val Ser Gln Ser Pro Arg Tyr Lys Val Ala Lys Arg Gly

1 5 10 15

Gln Asp Val Ala Leu Arg Cys Asp Pro Ile Ser Gly His Val Ser Leu

20 25 30

Phe Trp Tyr Gln Gln Ala Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr

35 40 45

Phe Gln Asn Glu Ala Gln Leu Asp Lys Ser Gly Leu Pro Ser Asp Arg

50 55 60

Phe Phe Ala Glu Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln

65 70 75 80

Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Ser

85 90 95

Asp Phe Gly Asn Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu Ser

100 105 110

Ile Leu Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe

115 120 125

Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val

130 135 140

Cys Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp

145 150 155 160

Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro

165 170 175

Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser

180 185 190

Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe

195 200 205

Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr

210 215 220

Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp

225 230 235 240

Gly Arg Ala Asp

<210> 53

<211> 9

<212> PRT

<213>artificial sequence (Artificial sequence)

<400> 53

Ile Leu Ser Pro Phe Leu Pro Leu Leu

1 5

Claims

1. a kind of T cell receptor (TCR), which is characterized in that it has the activity in conjunction with ILSPFLPLL-HLA A2 compound, and And the T cell receptor includes TCR α chain variable domain and TCR β chain variable domain, the TCR α chain variable domain includes 3 CDR regions, institute The consensus sequence for stating 3 CDR regions of TCR α chain variable domain is as follows,

CDR1 α: DRGSQS

CDR2 α: IYSNGD

CDR3 α: AVNLYAGNMLT, and contain at least one following mutation:

And/or the TCR β chain variable domain includes 3 CDR regions, the consensus sequence of 3 CDR regions of the TCR β chain variable domain is such as Under,

CDR1 β: SGHVS

CDR2 β: FQNEAQ

CDR3 β: ASSSDFGNQPQH,

Preferably, the TCR has CDR selected from the group below:

。

2. a kind of T cell receptor (TCR), which is characterized in that it has the activity in conjunction with ILSPFLPLL-HLA A2 compound, and Comprising TCR α chain variable domain and TCR β chain variable domain, the TCR occurs prominent in the α chain variable domain shown in SEQ ID NO:24 Become, the acid residues sites of the mutation include one or more of 92N, 93L, 94Y, 95A or 96G, wherein amino acid Residue numbering is numbered using shown in SEQ ID NO:24；

Preferably, the TCR α chain variable domain after mutation includes one or more amino acid residue selected from the group below: 92Q or 92A；93D, 93E, 93G, 93S or 93H；94P, 94Q, 94S or 94G；95S, 95T, 95W or 95D；96R,96K,96M,96Q, 96N, 96T, 96S or 96H, wherein numbering amino acid residues are numbered using shown in SEQ ID NO:24.

3. a kind of T cell receptor (TCR), which is characterized in that the TCR is selected from the group:

And/or the TCR is selected from the group:

。

4. a kind of multivalent TCR complex, which is characterized in that contain at least two TCR molecule, and at least one TCR therein Molecule is TCR described in any one of the claims.

5. a kind of nucleic acid molecules, which is characterized in that the nucleic acid molecules include to encode TCR as claimed in any one of claims 1-3 Nucleic acid sequence or its complementary series.

6. a kind of carrier, which is characterized in that the carrier contains nucleic acid molecules described in claim 5.

7. a kind of host cell, which is characterized in that in the host cell containing described in claim 6 carrier or dyeing Nucleic acid molecules described in the claim 5 of external source are integrated in body.

8. a kind of isolated cell, which is characterized in that the cell expresses TCR of any of claims 1-3.

9. a kind of pharmaceutical composition, which is characterized in that the composition contains pharmaceutically acceptable carrier and claim Cell described in TCR compound described in TCR described in any one of 1-3 or claim 4 or claim 8.

10. a kind of method for treating disease, which is characterized in that including in object in need for the treatment of application claim 1-3 Cell or claim 9 described in TCR compound described in TCR described in one or claim 4 or claim 8 Described in pharmaceutical composition.

11. TCR compound or claim 8 described in the described in any item T cell receptors of claim 1-3, claim 4 Described in cell purposes, which is characterized in that be used to prepare treatment tumour drug.

12. a kind of method for preparing T cell receptor as claimed in any one of claims 1-3, which is characterized in that comprising steps of

(i) host cell as claimed in claim 7 is cultivated, to express T cell receptor as claimed in any one of claims 1-3；

(ii) isolated or purified goes out the T cell receptor.